Farnsworth-Munsell 100 Hue Test

Farnsworth-Munsell 100 Hue Test
Name	Farnsworth-Munsell 100 Hue Test
Purpose	Color discrimination assessment
Developer	Dean Farnsworth; Munsell
Introduced	1940s

Contents

Farnsworth-Munsell 100 Hue Test The Farnsworth-Munsell 100 Hue Test is a psychophysical color arrangement test developed to quantify hue discrimination ability. It is used in clinical, industrial, and research settings to assess color vision performance in populations ranging from patients seen by Mayo Clinic clinicians to employees of NASA contractors, and it has informed standards used by organizations such as International Commission on Illumination and American Medical Association. The test’s design, scoring methodology, and applications intersect with work by figures and institutions including Dean Farnsworth, Munsell, Harvard University, Johns Hopkins Hospital, National Institutes of Health, University of Cambridge, Stanford University, and Massachusetts Institute of Technology.

Overview

The test measures ability to perceive small shifts in hue by requiring arrangement of colored caps into continuous hue sequences; it has been compared and contrasted with other assessments used by Royal College of Ophthalmologists settings and by research groups at University of Oxford and Karolinska Institutet. Historically influential in color science alongside contributions from Albert Munsell and experimental work associated with Maxwell, it has been referenced in standards promulgated by bodies like British Standards Institution and regulatory frameworks used by Federal Aviation Administration and European Space Agency. Prominent researchers and clinicians including those affiliated with Johns Hopkins Hospital, University College London, Columbia University, University of California, Berkeley, and University of Michigan have used the test in investigations spanning ophthalmology, neurology, and occupational health.

The apparatus consists of 85 movable colored caps grouped into four trays; participants order caps to create perceptually uniform hue sequences under controlled viewing conditions specified by standards from organizations such as International Organization for Standardization and testing laboratories like National Institute of Standards and Technology. Test administration protocols have been adopted by clinical centers including Cleveland Clinic, Mayo Clinic, and research programs at University of Pennsylvania and University of Washington. Lighting recommendations often reference illuminants and procedures developed in collaboration with institutions such as Royal Photographic Society affiliates and colorimetry research at Massachusetts Institute of Technology. Test administration is commonly performed by practitioners from institutions including Mount Sinai Hospital and Karolinska Institutet in studies involving cohorts from Harvard Medical School and Yale School of Medicine.

Scoring yields a total error score and sectoral error patterns that map to chromatic axes comparable to analyses used by researchers at University of Cambridge and University of Oxford. Interpretation of error distributions is performed in clinics such as Bascom Palmer Eye Institute and laboratories at Columbia University to distinguish protan, deutan, or tritan type deficits, and has been correlated with clinical findings from centers like Massachusetts Eye and Ear and Wills Eye Hospital. Epidemiological studies using the test have been conducted by teams at National Institutes of Health and Centers for Disease Control and Prevention to characterize population prevalence and occupational screening outcomes for agencies such as Federal Aviation Administration and European Aviation Safety Agency.

Clinically the test is used by ophthalmologists and neuro-ophthalmologists at institutions including Mayo Clinic, Johns Hopkins Hospital, and Bascom Palmer Eye Institute to evaluate acquired color defects from conditions studied at Cleveland Clinic and Massachusetts General Hospital such as optic neuritis, macular disease, and drug-induced dyschromatopsia monitored in trials at National Institutes of Health and pharmaceutical research at Roche and Pfizer. In research, laboratories at Stanford University, University of California, San Francisco, University College London, and Karolinska Institutet have applied the test to studies on aging, genetics, and neural correlates of color processing, often alongside imaging centers at National Institutes of Health and Wellcome Trust-funded projects.

Criticisms—raised in literature from groups at University of Cambridge, University of Oxford, and reviewers associated with British Journal of Ophthalmology—include lengthy administration time, influence of lighting and adaptation conditions discussed by International Commission on Illumination, and reduced sensitivity for mild dyschromatopsias in some populations studied at Johns Hopkins Hospital and Karolinska Institutet. Concerns about practice effects and inter-laboratory variability have been noted in multicenter studies coordinated by National Institutes of Health and peer-reviewed by journals connected with American Academy of Ophthalmology discourse.

Related instruments and shortened variants include the Farnsworth D-15 test used in occupational screening by agencies such as Federal Aviation Administration and computerized adaptations developed at Massachusetts Institute of Technology, Stanford University, and University of California, Berkeley. Comparative work with anomaloscope techniques and tests used in research at University of Cambridge, University College London, Karolinska Institutet, and clinical protocols from Mayo Clinic informs selection of instruments for specific purposes in settings including trials at National Institutes of Health and industrial screening by NASA contractors.

Category:Color vision tests